

# *In Vivo* Effect of Flucloxacillin in Experimental Endocarditis Caused by *mecC*-positive *Staphylococcus aureus* Showing Temperature-Dependent Susceptibility *In Vitro*

Stefano Mancini,<sup>a</sup> Frédéric Laurent,<sup>b</sup> Tiago R. Veloso,<sup>a\*</sup> Marlyse Giddey,<sup>a</sup> Jacques Vouillamoz,<sup>a</sup> François Vandenesch,<sup>b</sup> Philippe Moreillon,<sup>a</sup> José M. Entenza<sup>a</sup>

Department of Fundamental Microbiology, University of Lausanne, Lausanne, Switzerland<sup>a</sup>; National Reference Centre for Staphylococci, Hospices Civils de Lyon, International Center of Infectious Research, INSERM U1111, University of Lyon, Lyon, France<sup>b</sup>

**Methicillin-resistant *Staphylococcus aureus* (MRSA) carrying the *mecC* gene (*mecC*-MRSA) exhibited at 37°C MICs of oxacillin close to those of methicillin-susceptible *S. aureus* (MSSA). We investigated whether at this temperature, *mecC*-MRSA strains respond to flucloxacillin treatment like MSSA strains, using a rat model of endocarditis. Flucloxacillin (human-like kinetics of 2 g intravenously every 6 h) cured 80 to 100% of aortic vegetations infected with five different *mecC*-MRSA strains. These results suggest that *mecC*-MRSA infections may successfully respond to treatment with  $\beta$ -lactams.**

Methicillin-resistant *Staphylococcus aureus* (MRSA), isolated for the first time in the 1960s (1), developed resistance against methicillin and other  $\beta$ -lactam antibiotics through the acquisition of *mecA*, a gene encoding the penicillin binding protein 2a (PBP2a) (2). In 2011, a novel *mecA* homologue, *mecC* (3), was identified in bovine and human MRSA isolates (4–8). Although the incidence of *mecC*-MRSA is low (8–10), these strains cause severe infections in humans (11, 12).

Most *mecC*-MRSA isolates exhibit MICs of oxacillin less than or slightly greater than the MIC breakpoint of a susceptible strain ( $\leq 2$  mg/liter), and no clear distinction from methicillin-susceptible *S. aureus* (MSSA) isolates can be made (13, 14). Furthermore, the activity of the *mecC* product, namely, PBP2c (15), appears to be thermosensitive, with a decline at 37°C (16). This raises the question as to whether *mecC*-MRSA infections should be considered like *mecA*-MRSA infections and treated with vancomycin (17) or like MSSA infections, generally treated with  $\beta$ -lactams, such as flucloxacillin (18). In this study, we investigated the *in vivo* activity of flucloxacillin on *mecC*-MRSA strains using a rat model of endocarditis.

Five *mecC*-MRSA strains, two of animal origin (NCTC 13552 and 1100) and three of human origin (strain 820, from an infected knee [6], and the urine and screening strains S090 and S129 [19]), were used. *S. aureus* strains ATCC 29213 (MSSA) and Mu50 (*mecA*-MRSA) were used as controls. The MICs of oxacillin and ceftiofuran were determined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (20). The MICs were interpreted according to the CLSI guidelines after incubation at 30°C and 37°C for 24 h. Population analysis profiles (PAPs) were performed on agar plates containing 2-fold serial dilutions of oxacillin and on oxacillin-free plates, as described previously (21). Colony numbers were enumerated after 48 h of incubation at 30°C and 37°C. Oxacillin-induced killing was assessed by time-kill assays using strains NCTC 13552 and S129. The flasks containing Mueller-Hinton broth supplemented with 2% NaCl were inoculated with  $10^6$  CFU/ml of bacteria, exposed to oxacillin (10 mg/liter), and incubated at 30°C or 37°C. The concentration of oxacillin approximated trough levels in the sera of rats and was either

less than or greater than the MICs for the organisms when tested at a temperature of 30°C or 37°C, respectively (see below).

The production of catheter-induced aortic vegetations and the installation of the infusion pump device to deliver flucloxacillin were performed in rats as described previously (22, 23). Endocarditis was induced 24 h after catheterization by intravenous (i.v.) challenge of the animals with  $10^5$  CFU of each test *mecC*-MRSA strain and the *mecA*-MRSA Mu50 strain. Therapy with flucloxacillin (human-like kinetics of 2 g i.v. every 6 h) was started 12 h later and lasted for 3 days. Control rats were sacrificed at the onset of treatment and treated rats at 8 h after the end of the last antibiotic dose. A group of 3 to 4 control animals was also sacrificed at the same time as the treated animals. After the sacrifice, aortic valve vegetations were removed and processed as described previously (24) for colony counts. All protocols for animal studies were reviewed and approved by the Cantonal Committee on Animal Experiments of the State of Vaud, Switzerland (permit number 879.9).

MICs are shown in Table 1. All of the *mecC*-MRSA isolates were formally resistant to oxacillin at 30°C and susceptible at 37°C (threshold,  $\leq 2$  mg/liter). All but the S820 isolate were resistant to ceftiofuran (threshold,  $\geq 8$  mg/liter) at both 30°C and 37°C. Figure 1 shows that upon exposure to oxacillin at 30°C, *mecC*-MRSA isolates exhibited subpopulations of resistant bacteria at concentra-

Received 6 November 2014 Returned for modification 3 December 2014

Accepted 15 January 2015

Accepted manuscript posted online 20 January 2015

Citation Mancini S, Laurent F, Veloso TR, Giddey M, Vouillamoz J, Vandenesch F, Moreillon P, Entenza JM. 2015. *In vivo* effect of flucloxacillin in experimental endocarditis caused by *mecC*-positive *Staphylococcus aureus* showing temperature-dependent susceptibility *in vitro*. *Antimicrob Agents Chemother* 59: 2435–2438. doi:10.1128/AAC.04733-14.

Address correspondence to José M. Entenza, jose.entenza@unil.ch.

\* Present address: Tiago R. Veloso, Centre for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.

Copyright © 2015, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.04733-14

TABLE 1 MICs of oxacillin and cefoxitin<sup>a</sup>

Strain	MIC (mg/liter)			
	Oxacillin		Cefoxitin	
	30°C	37°C	30°C	37°C
NCTC 13552	8–16	0.5–1	64	8
1100	16	0.5–2	32	8
820	4	0.5–1	8	4
S090	16	1	32	16
S129	16–32	0.5–2	64	16–32

<sup>a</sup> MICs were determined at least three times independently at the indicated temperatures in Mueller-Hinton broth supplemented with 2% NaCl.

tions up to 32 mg/liter. However, these oxacillin-resistant subpopulations virtually disappeared at 37°C. Moreover, with the exception of strain NCTC 13552, for which resistant subpopulations emerged on 8-mg/liter oxacillin plates, the remaining four tested *mecC*-MRSA isolates displayed a profile similar to that of MSSA ATCC 29213 (growth at up to 4 mg/liter oxacillin). The *mecA*-MRSA Mu50 strain displayed homogeneous resistance to oxacillin, as reported previously (25). The rate of killing by oxacillin of the selected isolates NCTC 13552 and S129 was also affected by temperature (Fig. 2). After 24 h of incubation at 30°C, oxacillin did not display any antibacterial activity (Fig. 2A). In contrast, after 24 h of incubation at 37°C, oxacillin caused a 2-log<sub>10</sub> CFU/ml decrease in cell viability (Fig. 2B). The results of experimental endocarditis are shown in Table 2. Vegetations of




FIG 1 Phenotypic expression of oxacillin resistance in *mecC*-MRSA strains assessed by population analysis. Large inocula (ca. 10<sup>9</sup> CFU) of the test strains were spread onto Mueller-Hinton agar plates supplemented with 2% NaCl and containing increasing concentrations of oxacillin and on oxacillin-free plates. The plates were incubated at 30°C (A) or 37°C (B) for 48 h, and then the CFU were enumerated. Each assay was performed on two to three independent occasions.




FIG 2 Killing curves of *mecC*-MRSA isolates NCTC 13552 and S129 by oxacillin (OXA) at a concentration of 10 mg/liter, simulating antibiotic levels achieved at trough in rat or human serum. The flasks containing the test strains not exposed (controls) or exposed to OXA were incubated at 30°C (A) or 37°C (B) for 24 h. Results are representative of two independent experiments.

control animals sacrificed at the start of treatment were all infected and contained high (median, 8.5 log<sub>10</sub> CFU/g) bacterial counts. The peak (30 min), the trough (6 h) (mean ± standard deviation), and the area under the curve values for flucloxacillin in rat serum were 174 ± 50 mg/liter, 16 ± 5 mg/liter, and 213 mg · h/liter, respectively. The half-life was ca. 1 h. These values were close to those reported in humans, i.e., 125 to 154 mg/liter, 14 mg/liter, 178.6 mg · h/liter, and 1 h, respectively (26, 27). Flucloxacillin sterilized 80 to 100% of vegetations infected with *mecC*-MRSA strains and reduced the vegetation counts by >6 log<sub>10</sub> CFU/g compared to those of controls (*P* < 0.005). Bacteria recovered from vegetations showed unchanged oxacillin susceptibility. All of

TABLE 2 Outcome of 3-day treatment with flucloxacillin of experimental endocarditis caused by *mecC*-MRSA isolates

Strain	No. of sterile vegetations/total no. of vegetations (%; median [range] log <sub>10</sub> CFU/g of vegetation for treatment group:	
	Control	Flucloxacillin <sup>a</sup>
NCTC 13552	0/5 (0; 8.5 [6.7–8.9])	10/11 (91 <sup>b</sup> ; 2.0 [2.0–2.7]) <sup>c</sup>
1100	0/5 (0; 8.8 [8.1–9.1])	9/9 (100); 2.0 [2.0–2.0])
820	0/5 (0; 7.7 [6.4–9.0])	6/8 (75); 2.0 [2.0–4.1]) <sup>c</sup>
S090	0/5 (0; 8.0 [7.6–9.4])	9/10 (90 <sup>b</sup> ; 2.0 [7.0–3.2]) <sup>c</sup>
S129	0/5 (0; 8.7 [8.3–9.1])	8/10 (80 <sup>b</sup> ; 2.0 [2.0–6.0]) <sup>c</sup>

<sup>a</sup> Simulation in rats of human pharmacokinetics following 2 g i.v. every 6 h.

<sup>b</sup> *P* < 0.05 compared to untreated controls by Fisher's exact test.

<sup>c</sup> *P* < 0.005 compared to untreated controls by Mann-Whitney test.

the vegetations from control animals sacrificed at the end of treatment were heavily infected (median, 9.8 log<sub>10</sub> CFU/g) (data not shown). Flucloxacillin was totally ineffective against the *mecA*-MRSA Mu50 isolate (0/6 [0%] sterile valves).

In the current study, we observed a clear effect of the temperature on the activity of oxacillin against *mecC*-MRSA isolates *in vitro*. Indeed, all five tested *mecC*-MRSA isolates showed resistance to oxacillin in assays performed at 30°C but were susceptible at 37°C. These results are in agreement with those of previous studies with the NCTC 13552 (formerly LGA251) strain (16). Temperature is known to have an impact *in vitro* on the susceptibility of heterogeneous *mecA*-MRSA strains to oxacillin (28–30), possibly due to PBP2a downregulation (31) or enzymatic inactivation at ≥37°C (2). Our results indicate that thermosensitive heterogeneous expression of oxacillin resistance is also present in *mecC*-MRSA isolates. However, in contrast with *mecA*-MRSA isolates, where resistant subpopulations grew on plates containing >1,000 mg/liter oxacillin at 37°C (29), *mecC*-MRSA isolates showed no subpopulations emerging on plates containing >32 mg/liter oxacillin. Furthermore, rats with endocarditis induced by *mecC*-MRSA were successfully treated with human-like kinetics of flucloxacillin. We attribute these positive outcomes to the body temperature (≥37°C) present in animals with endocarditis (32). Indeed, at this temperature, the MICs of oxacillin for the tested isolates were ≤2 mg/liter, and plasma concentrations of flucloxacillin were greater than the MIC of the organisms throughout the dosing interval.

These data suggest consideration of β-lactams as an option for the treatment of *mecC*-MRSA infections. However, due to the presence of heterogeneous oxacillin-resistant subpopulations, albeit at low frequency, caution is advised in the use of these drugs. Indeed, in an analogous situation, resistant subpopulations in *mecA*-MRSA strains negatively impacted the β-lactam therapy of MRSA infections (33).

## ACKNOWLEDGMENTS

This work was supported in part by grant 310030-143799/1 from the Swiss National Science Foundation.

We thank Ariane Deplano, Université Libre de Bruxelles, Brussels, Belgium, for sending us *mecC* *S. aureus* isolates S090 and S129.

We declare no conflicts of interest.

## REFERENCES

- Jevons MP, Coe AW, Parker MT. 1963. Methicillin resistance in staphylococci. *Lancet* i:904–907.
- Hartman BJ, Tomasz A. 1984. Low-affinity penicillin-binding protein associated with beta-lactam resistance in *Staphylococcus aureus*. *J Bacteriol* 158:513–516.
- Ito T, Hiramatsu K, Tomasz A, de Lencastre H, Perreten V, Holden MT, Coleman DC, Goering R, Giffard PM, Skov RL, Zhang K, West H, O'Brien F, Tenover FC, Oliveira DC, Boyle-Vavra S, Laurent F, Kearns AM, Kreiswirth B, Ko KS, Grundmann H, Sollid JE, John JF, Jr, Daum R, Soderquist B, Buist G, International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). 2012. Guidelines for reporting novel *mecA* gene homologues. *Antimicrob Agents Chemother* 56:4997–4999. <http://dx.doi.org/10.1128/AAC.01199-12>.
- García-Álvarez L, Holden MT, Lindsay H, Webb CR, Brown DF, Curran MD, Walpole E, Brooks K, Pickard DJ, Teale C, Parkhill J, Bentley SD, Edwards GF, Girvan EK, Kearns AM, Pichon B, Hill RL, Larsen AR, Skov RL, Peacock SJ, Maskell DJ, Holmes MA. 2011. Methicillin-resistant *Staphylococcus aureus* with a novel *mecA* homologue in human and bovine populations in the UK and Denmark: a descriptive study. *Lancet Infect Dis* 11:595–603. [http://dx.doi.org/10.1016/S1473-3099\(11\)70126-8](http://dx.doi.org/10.1016/S1473-3099(11)70126-8).
- Petersen A, Stegger M, Heltberg O, Christensen J, Zeuthen A, Knudsen LK, Urth T, Sorum M, Schouls L, Larsen J, Skov R, Larsen AR. 2013. Epidemiology of methicillin-resistant *Staphylococcus aureus* carrying the novel *mecC* gene in Denmark corroborates a zoonotic reservoir with transmission to humans. *Clin Microbiol Infect* 19:E16–E22. <http://dx.doi.org/10.1111/1469-0691.12036>.
- Laurent F, Chardon H, Haenni M, Bes M, Reverdy ME, Madec JY, Lagier E, Vandenesch F, Tristan A. 2012. MRSA harboring *mecA* variant gene *mecC*, France. *Emerg Infect Dis* 18:1465–1467. <http://dx.doi.org/10.3201/eid1809.111920>.
- Kriegeskorte A, Ballhausen B, Idelevich EA, Kock R, Friedrich AW, Karch H, Peters G, Becker K. 2012. Human MRSA isolates with novel genetic homolog, Germany. *Emerg Infect Dis* 18:1016–1018. <http://dx.doi.org/10.3201/eid1806.110910>.
- Paterson GK, Harrison EM, Holmes MA. 2014. The emergence of *mecC* methicillin-resistant *Staphylococcus aureus*. *Trends Microbiol* 22:42–47. <http://dx.doi.org/10.1016/j.tim.2013.11.003>.
- Basset P, Prod'homme G, Senn L, Greub G, Blanc DS. 2013. Very low prevalence of methicillin-resistant *Staphylococcus aureus* carrying the *mecC* gene in western Switzerland. *J Hosp Infect* 83:257–259. <http://dx.doi.org/10.1016/j.jhin.2012.12.004>.
- Paterson GK, Morgan FJ, Harrison EM, Cartwright EJ, Torok ME, Zadoks RN, Parkhill J, Peacock SJ, Holmes MA. 2014. Prevalence and characterization of human *mecC* methicillin-resistant *Staphylococcus aureus* isolates in England. *J Antimicrob Chemother* 69:907–910. <http://dx.doi.org/10.1093/jac/dkt462>.
- Barraud O, Laurent F, Francois B, Bes M, Vignon P, Ploy MC. 2013. Severe human bone infection due to methicillin-resistant *Staphylococcus aureus* carrying the novel *mecC* variant. *J Antimicrob Chemother* 68:2949–2950. <http://dx.doi.org/10.1093/jac/dkt274>.
- García-Garrote F, Cercenado E, Marin M, Bal M, Trincado P, Corredoira J, Ballesteros C, Pita J, Alonso P, Vindel A. 2014. Methicillin-resistant *Staphylococcus aureus* carrying the *mecC* gene: emergence in Spain and report of a fatal case of bacteraemia. *J Antimicrob Chemother* 69:45–50. <http://dx.doi.org/10.1093/jac/dkt327>.
- Fluit AC. 2011. What to do with MRSA with a novel *mec* gene? *Lancet Infect Dis* 11:580–581. [http://dx.doi.org/10.1016/S1473-3099\(11\)70180-3](http://dx.doi.org/10.1016/S1473-3099(11)70180-3).
- Skov R, Larsen AR, Kearns A, Holmes M, Teale C, Edwards G, Hill R. 2014. Phenotypic detection of *mecC*-MRSA: cefoxitin is more reliable than oxacillin. *J Antimicrob Chemother* 69:133–135. <http://dx.doi.org/10.1093/jac/dkt341>.
- Ballhausen B, Kriegeskorte A, Schleimer N, Peters G, Becker K. 2014. The *mecA* homolog *mecC* confers resistance against beta-lactams in *Staphylococcus aureus* irrespective of the genetic strain background. *Antimicrob Agents Chemother* 58:3791–3798. <http://dx.doi.org/10.1128/AAC.02731-13>.
- Kim C, Milheirico C, Gardete S, Holmes MA, Holden MT, de Lencastre H, Tomasz A. 2012. Properties of a novel PBP2A protein homolog from *Staphylococcus aureus* strain LGA251 and its contribution to the beta-lactam-resistant phenotype. *J Biol Chem* 287:36854–36863. <http://dx.doi.org/10.1074/jbc.M112.395962>.
- Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children: executive summary. *Clin Infect Dis* 52:285–292. <http://dx.doi.org/10.1093/cid/cir034>.
- Rayner C, Munchhof WJ. 2005. Antibiotics currently used in the treatment of infections caused by *Staphylococcus aureus*. *Intern Med J* 35(suppl 2):S3–S16.
- Deplano A, Vandendriessche S, Nonhoff C, Denis O. 2014. Genetic diversity among methicillin-resistant *Staphylococcus aureus* isolates carrying the *mecC* gene in Belgium. *J Antimicrob Chemother* 69:1457–1460. <http://dx.doi.org/10.1093/jac/dku020>.
- Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 9th ed. Document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
- Que YA, Entenza JM, Francioli P, Moreillon P. 1998. The impact of

- penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant *Staphylococcus aureus*. *J Infect Dis* 177:146–154. <http://dx.doi.org/10.1086/513805>.
22. Héraïef E, Glauser MP, Freedman LR. 1982. Natural history of aortic valve endocarditis in rats. *Infect Immun* 37:127–131.
  23. Fluckiger U, Moreillon P, Blaser J, Bickle M, Glauser MP, Francioli P. 1994. Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats. *Antimicrob Agents Chemother* 38:2846–2849. <http://dx.doi.org/10.1128/AAC.38.12.2846>.
  24. Entenza JM, Vouillamoz J, Glauser MP, Moreillon P. 1997. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 41:1662–1667.
  25. Chung M, Antignac A, Kim C, Tomasz A. 2008. Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant *Staphylococcus aureus* to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. *Antimicrob Agents Chemother* 52:2709–2717. <http://dx.doi.org/10.1128/AAC.00266-08>.
  26. Bergan T, Engeset A, Olszewski W, Ostby N, Solberg R. 1986. Extravascular penetration of highly protein-bound flucloxacillin. *Antimicrob Agents Chemother* 30:729–732. <http://dx.doi.org/10.1128/AAC.30.5.729>.
  27. Frank U, Schmidt-Eisenlohr E, Schlosser V, Spillner G, Schindler M, Daschner FD. 1988. Concentrations of flucloxacillin in heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery. *Antimicrob Agents Chemother* 32:930–931. <http://dx.doi.org/10.1128/AAC.32.6.930>.
  28. Thornsberry C, Caruthers JQ, Baker CN. 1973. Effect of temperature on the in vitro susceptibility of *Staphylococcus aureus* to penicillinase-resistant penicillins. *Antimicrob Agents Chemother* 4:263–269. <http://dx.doi.org/10.1128/AAC.4.3.263>.
  29. Hartman BJ, Tomasz A. 1986. Expression of methicillin resistance in heterogeneous strains of *Staphylococcus aureus*. *Antimicrob Agents Chemother* 29:85–92. <http://dx.doi.org/10.1128/AAC.29.1.85>.
  30. Mateos-Mora M, Knapp CC, Washington JA, II. 1988. Characterization of resistance phenotype and cephalosporin activity in oxacillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 32:170–174. <http://dx.doi.org/10.1128/AAC.32.2.170>.
  31. Madiraju MV, Brunner DP, Wilkinson BJ. 1987. Effects of temperature, NaCl, and methicillin on penicillin-binding proteins, growth, peptidoglycan synthesis, and autolysis in methicillin-resistant *Staphylococcus aureus*. *Antimicrob Agents Chemother* 31:1727–1733. <http://dx.doi.org/10.1128/AAC.31.11.1727>.
  32. Wang ML, Zhang Y, Fan M, Guo YJ, Ren WD, Luo EJ. 2013. A rabbit model of right-sided *Staphylococcus aureus* endocarditis created with echocardiographic guidance. *Cardiovasc Ultrasound* 11:3. <http://dx.doi.org/10.1186/1476-7120-11-3>.
  33. Chambers HF. 1997. Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications. *Clin Microbiol Rev* 10:781–791.